Thibault Tricard

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 128 citations · Full text

Urology, Oncology, Genitourinary Cancer +7

Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma

Guillaume Davidson, Alexandra Helleux, Yann Vano et al. · Cancer Research · 2023 · 74 citations

Evaluation of axitinib to downstage <scp>cT</scp> 2a renal tumours and allow partial nephrectomy: a phase II study

C. Lebâcle, Karim Bensalah, Jean‐Christophe Bernhard et al. · British Journal of Urology · 2018 · 49 citations

SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance

Bujamin Vokshi, Guillaume Davidson, Nassim Tawanaie Pour Sedehi et al. · Nature Communications · 2023 · 32 citations · Full text

Safety and oncologic efficacy of percutaneous MRI-guided cryoablation of intraparenchymal renal cancers

Pierre De Marini, Roberto Luigi Cazzato, Julien Garnon et al. · Diagnostic and Interventional Imaging · 2021 · 26 citations

Oncologic Efficacy, Urology, Surgical Oncology +9